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 Th e paradigm of hemodialysis has evolved 
from a life-saving treatment for a minority 
of patients with acute kidney injury to a life-
sustaining therapy for many thousands of 
patients with chronic kidney disease stage 
5 worldwide. Although hemodialysis treat-
ments have become established as part of 
routine medical practice, moving out from 
specialized academic centers to free-stand-
ing satellite dialysis centers and to the 
patient ’ s home, survival remains disappoint-
ing, with 5-year UK survival rates around 
46 % , compared with 44 % for ovarian can-
cer, and 54 % for colonic cancer. In addition, 
hemodialysis is expensive, consuming 2 – 3 % 
of the overall UK health-care budget despite 
treating only 0.04 % of the population. 
 As the survival of kidney transplant 
patients and those with stable chronic kid-
ney disease stages 3 – 4 is greater than that of 
hemodialysis patients, it has been argued for 
many years that the amount of endo genous 
renal function or renal replacement therapy 
aff ects survival. Th e National Cooperative 
Dialysis Study, the fi rst randomized control-
led study of dialysis dose, used an assess-
ment of urea clearance corrected for body 
water ( Kt / V urea ) and defined a sessional 
 ‘ adequacy ’ threshold for thrice-weekly 
hemodialysis of 0.9, below which complica-
tion-free survival was compromised within 
months. 1 Later observational studies sug-
gested that higher sessional doses were asso-
ciated with improved outcomes, and by 
consensus the sessional  Kt / V urea target was 
raised to 1.2. 2 A second randomized con-
trolled study, the HEMO Study, demon-
strated that targeting doses to a sessional 
 Kt / V urea of 1.45 did not appear to improve 
survival further, 3 although subgroup analy-
sis suggested women may benefit from 
higher  Kt / V urea doses, fueling suggestions 
that prescribing dialysis to achieve  Kt / V urea 
targets may lead to underdosing of women 
and small men. 4 Observational studies typ-
ically based on home-hemodialysis cohorts 
or single centers reported improved survival 
of patients treated with more frequent 
hemodialysis and extended hours of hemo-
dialysis. 5 As these studies were confounded 
by patient selection bias, the Frequent 
Hemodialysis Network (FHN) Trial Group 
organized two prospective randomized tri-
als to study the eff ect of increasing the dose 
of standard thrice-weekly dialysis, by 
increasing dialysis frequency. Th e fi rst study 
examined the effect of six short weekly 
hemodialysis sessions, averaging 154  min, 
in 125 patients, compared with thrice-
weekly dialysis for an average of 213  min in 
120 patients, delivering an average weekly 
standard  Kt / V urea , adjusted for session dura-
tion and frequency, of 3.6 compared with 
2.57 (40 % average increase), although the 
average weekly dialysis time was increased 
by only 22 % (12.7 vs. 10.4  h, respectively). 6 
Th is relatively greater increase in  Kt / V urea 
is due to the higher urea concentration gra-
dient during the early phase of the dialysis 
session ( Figure 1 ). This study lasted 12 
months, and there was no difference in 
patient survival; however, two predeter-
mined co-primary end points — mortality or 
increase in left  ventricular mass, and mortal-
ity or decrease in physical health composite 
score — were signifi cantly lower in the more 
frequent hemodialysis group. Th e second 
study (Rocco  et al. , 7 this issue) planned to 
examine the eff ect of both increased fre-
quency and duration of sessions, by recruit-
ing 250 patients randomized to six in-center 
nocturnal dialysis sessions with standard 
thrice-weekly dialysis. However, only 87 
were recruited, who then had unsupervised 
home hemodialysis, reducing the power of 
the study. 7 Despite a greater dose of   Kt / V urea 
delivered with more frequent nocturnal 
dialysis (mean 5 vs. 2.9 sessions per week, 
average session 379 vs. 256  min, 30.8 vs. 
12.6  h hemodialysis / week, weekly standard 
 Kt / V 5.0 vs. 2.9), and greater phosphate 
removal, there was no diff erence in 1-year 
mortality, or in the same two co-primary 
end points used in the FHN shorter-hours 
study . Although the nocturnal study was 
most likely underpowered, and confounded 
by improvements in the control group from 
switching to home hemodialysis. In addi-
tion, greater delivered  Kt / V urea did not 
improve cognitive performance, self-
reported depression, or serum albumin 
or reduce erythropoietin requirements 
in either trial. 
 Although the amount of dialysis deliv-
ered is assessed in terms of urea clearance, 
urea is only one of many metabolites that 
accumulate in chronic kidney disease 
stage 5, and there has been renewed 
interest in other azotemic toxins. As the 
role and importance of individual toxins 
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remain to be elucidated,   2 -microglobulin 
has often been used as a surrogate for 
middle-sized molecular azotemic toxins. 
Th e HEMO Study reported an increased 
risk of death with increasing serum   2 -
microglobulin concentrations, 8 but was 
unable to demonstrate an overall survival 
benefi t with high-fl ux membranes, with 
greater removal, middle molecule includ-
ing   2 -microglobulin. However, subgroup 
analysis suggested that high-fl ux mem-
branes conferred a survival advantage for 
prevalent patients established on dialysis 
for more than 3.6 years. 3 Th e Membrane 
Permeability Outcome study also failed to 
show an overall survival benefi t of high-
fl ux membranes, but there was a survival 
advantage for high-risk patients. 9 The 
FHN Trial Group used high-fl ux dialyzers 
for both groups. However, as diffusive 
clearance depends on size and free plasma 
water concentration, clearance of middle 
molecules is predominantly limited by 
dialysis-session time, and removal of   2 -
microglobulin and protein-bound toxins 
would have been greater in the more-fre-
quent nocturnal group. Indeed, phosphate 
removal was so eff ective in the nocturnal 
group that dialysate phosphate supple-
mentation was required. So why was there 
no improvement in mortality, or in cogni-
tive performance, self-reported depres-
sion, or serum albumin, and no reduction 
in erythropoietin-stimulating agents? Th is 
was a 12-month study, and accumulation 
and toxicity of azotemic middle molecules 
probably takes years; and some 25 % of 
subjects dialyzed fewer than fi ve times per 
week. In addition, only 87 % completed 
the study, and many had dialyzed for less 
than 12 months and so retained residual 
renal function. 
 Removal of azotemic middle molecules 
can be further increased by the addition 
of convection, and studies of hemodiafi l-
tration have reported lower serum   2 -
microglobulin and phosphate levels 
in comparison with high-flux hemo-
dialysis. 10 Th e question of whether these 
surrogates based on improved middle-
molecule removal translate into improved 
patient survival led to a number of pro-
spective multicenter trials. Some of these 
trials have now been completed and are 
expected to report shortly. If these trials 
show a survival benefi t for hemodiafi ltra-
tion, then this will support a role for the 
toxicity of azotemic middle molecules. 
Although some of these putative toxins, 
such as serum   2 -microglobulin, can be 
removed by hemodiafi ltration and free 
light chains by high-permeability dialyzer 
membranes, removal of protein-bound 
azotemic toxins is typically limited by 
the equilibrium rate between free and 
protein-bound forms. 
 Although much attention has centered 
on small- and middle-molecule removal, 
dialysis is much more than simply urea 
clearance. Dialysis treatments are equally 
prescribed to achieve homeostasis, by cor-
recting volume overload, sodium balance, 
and metabolic acidosis and maintaining 
divalent ion balance. Th e advent of multi-
frequency bioimpedance devices and 
biomarkers of volume overload has shown 
that many hemodialysis patients fail to 
achieve adequate volume control and 
remain permanently volume overloaded 
throughout the dialysis week. Many 
patients with chronic kidney disease stage 
5 entering hemodialysis programs have 
hypertension, left  ventricular hypertro-
phy, and abnormal pulse-wave velocity. 
Not surprisingly, cardiovascular mortality 
remains the major cause of death of hemo-
dialysis patients. One major advantage of 
more frequent hemodialysis is that shorter 
interdialysis intervals lead to reduced 
intradialytic weight gains. Th us the more 
frequent daily dialysis and nocturnal FHN 
groups had lower total ultrafi ltration and 
ultrafi ltration requirements per treatment 
session, resulting in a lower frequency of 
intradialytic hypotension. 
 In addition, not only did blood pressure 
control improve during the 12-month stud-
ies in both more frequent dialysis groups, 
but patients also required fewer antihyper-
tensive medications. Echocardiography 
and pulse-wave velocity are aff ected by vol-
ume status, such that assessments of left  
ventricular mass differ depending on 
whether echocardiography is performed 
before, aft er, or on the non-dialysis day. Th e 
FHN studies measured left ventricular 
mass with magnetic resonance imaging, 
which is less aff ected by volume status. Left  
ventricular mass was signifi cantly reduced 
only in the more frequent daily dialysis 
study and not in the nocturnal home 
hemodialysis study. Although there may be 
many possible explanations, in the more 
frequent dialysis study, the average stand-
ard dialysis-session time for the thrice-
weekly treatment groups was only 213  min, 
compared with 256  min in the home hemo-
dialysis study. Th erefore, it is most likely 
that those patients treated with shorter 
session times failed to achieve adequate 
sodium removal and were more likely 
to be volume overloaded during the 
dialysis week. Th us, diff erences in volume 
status may partially explain the diff erent 
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 Figure 1  |  Solute kinetics in hemodialysis. Change in plasma concentration of solute 1 (S1), 
which readily moves from intracellular compartment to plasma, such as urea, and solute 2 (S2), 
which moves slowly from intracellular compartment to plasma, such as a middle molecule or 
protein-bound toxin. 
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study fi ndings. In the smaller, nocturnal 
study the greater amount of dialysis deliv-
ered in the standard-treatment arm may 
have reduced diff erences in volume status 
due to the fact that 25 % of nocturnal 
patients dialyzed fewer than fi ve times per 
week. 
 Although more frequent treatments were 
advantageous in terms of blood pressure 
control and reduced intradialytic hypoten-
sion and phosphate control, were there any 
adverse eff ects? In both studies there were 
an increased number of access interven-
tions, particularly with fi stulae in the noc-
turnal hemodialysis group. Th is experience 
diff ered from those in observational reports 
of more frequent dialysis and requires 
explanation. Unfortunately, the reasons for 
access interventions were not elucidated, 
and whether this related to the type of 
access and needling technique was not 
specifi ed. Th us, although there are advan-
tages to more frequent dialysis, more fre-
quent needling may potentially lead to 
more access interventions. 
 DISCLOSURE 
 The author declared no competing interests. 
 REFERENCES 
 1 .  Lowrie  EG ,  Laird  NM ,  Parker  TF  et al.  Effect of 
the hemodialysis prescription of patient 
morbidity: report from the National Cooperative 
Dialysis Study .  N Engl J Med  1981 ;  305 : 
 1176 – 1181 . 
 2 .  Morbidity and mortality of dialysis .  NIH Consens 
Statement  1993 ;  11 :  1 – 33 . 
 3 .  Eknoyan  G ,  Beck  GJ ,  Cheung  AK  et al.  Effect of 
dialysis dose and membrane flux in mainte nance 
hemodialysis .  N Engl J Med  2002 ;  347 :  2010 – 2019 . 
 4 .  Spalding  EM ,  Chandna  SM ,  Davenport  A  et al.  
 Kt/V underestimates the hemodialysis dose 
in women and small men .  Kidney Int  2008 ;  74 : 
 348 – 355 . 
 5 .  Lockridge  RS ,  Kjellstrand  CM .  Nightly home 
hemodialysis: outcome and factors associated 
with survival .  Hemodial Int  2011 ;  15 :  211 – 218 . 
 6 .  Chertow  GM ,  Levin  NW ,  Beck  GJ  et al.  In-center 
hemodialysis six times per week versus three times 
per week. FHN Trial Group .  N Engl J Med  2010 ;  363 : 
 2287 – 2300 . 
 7 .  Rocco  MV ,  Lockridge  Jr  RS ,  Beck  GJ  et al.  The effects 
of frequent nocturnal home hemodialysis: the 
Frequent Hemodialysis Network Nocturnal Trial . 
 Kidney Int  2011 ;  80 :  1080 – 1091 . 
 8 .  Cheung  AK ,  Rocco  MV ,  Yan  G  et al.  Serum beta-2 
microglobulin levels predict mortality in dialysis 
patients: results of the HEMO study .  J Am Soc 
Nephrol  2006 ;  17 :  546 – 555 . 
 9 .  Locatelli  F ,  Martin-Malo  A ,  Hannedouche  T  et al. 
 Effect of membrane permeability on survival of 
hemodialysis patients .  J Am Soc Nephrol  2009 ;  20 : 
 645 – 654 . 
 10 .  Oates  T ,  Pinney  JH ,  Davenport  A .  Hemodiafiltration 
versus high-flux hemodialysis: effects on 
phosphate control and erythropoietin response . 
 Am J Nephrol  2011 ;  33 :  70 – 75 . 
